27.85
0.16 (0.58%)
| Penutupan Terdahulu | 27.69 |
| Buka | 27.83 |
| Jumlah Dagangan | 116,932 |
| Purata Dagangan (3B) | 275,373 |
| Modal Pasaran | 860,910,144 |
| Harga / Jualan (P/S) | 2.54 |
| Harga / Buku (P/B) | 0.720 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Nov 2025 |
| Margin Keuntungan | -13.94% |
| Margin Operasi (TTM) | -26.95% |
| EPS Cair (TTM) | -1.33 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 13.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.74% |
| Nisbah Semasa (MRQ) | 6.32 |
| Aliran Tunai Operasi (OCF TTM) | 9.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -42.21 M |
| Pulangan Atas Aset (ROA TTM) | -3.69% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | Fulgent Genetics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.30 |
|
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 33.42% |
| % Dimiliki oleh Institusi | 54.65% |
| Julat 52 Minggu | ||
| Median | 30.00 (7.72%) | |
| Jumlah | 1 Pegang | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 11 Nov 2025 | 30.00 (7.72%) | Pegang | 28.38 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GAO HANLIN | - | 27.53 | -1,331 | -36,642 |
| KIM PAUL | - | 27.53 | -3,004 | -82,700 |
| XIE JIAN | - | 27.53 | -4,711 | -129,694 |
| Jumlah Keseluruhan Kuantiti Bersih | -9,046 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -249,036 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 27.53 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KIM PAUL | Pegawai | 26 Jan 2026 | Dibuang (-) | 3,004 | 27.53 | 82,700 |
| XIE JIAN | Pegawai | 26 Jan 2026 | Dibuang (-) | 4,711 | 27.53 | 129,694 |
| GAO HANLIN | Pegawai | 26 Jan 2026 | Dibuang (-) | 1,331 | 27.53 | 36,642 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 22 Dec 2025 | Pengumuman | Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |